Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: A meta-analysis on their efcacy and safety
Số trang: 13
Loại file: pdf
Dung lượng: 5.64 MB
Lượt xem: 7
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
This study systematically reviewed the RCTs of combined atezolizumab and nab-paclitaxel in the treatment of TNBC and synthesize the evidence-based results on its efectiveness and adverse effects of it.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Triple negative breast cancer PD-L1 inhibitor Systematic review Meta-analysisGợi ý tài liệu liên quan:
-
19 trang 267 0 0
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 119 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0 -
11 trang 37 0 0
-
13 trang 36 0 0
-
Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image
10 trang 34 0 0 -
Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
9 trang 34 0 0 -
16 trang 34 0 0
-
11 trang 33 0 0
-
9 trang 33 0 0
-
CYP4B1 polymorphisms and the risk of breast cancer in Chinese women: A case-control study
14 trang 32 0 0 -
11 trang 32 0 0